Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_assertion type Assertion NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_head.
- NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_provenance.
- NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_assertion evidence source_evidence_literature NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_provenance.
- NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_assertion SIO_000772 15948676 NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_provenance.
- NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_assertion wasDerivedFrom befree-20150227 NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_provenance.
- NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_assertion wasGeneratedBy ECO_0000203 NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_provenance.